Novartis Selects Alteogen Technology in Potential $3.22 Billion Subcutaneous-Drug Deal on September 03, 2026 ALT-B4 Alteogen berahyaluronidase alfa Biological Factors Drug Delivery Systems Hybrozyme licensing agreement Novartis Subcutaneous Injections +